Newnorm clinical trials

Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases

This study is looking at a new treatment called Newnorm for people with primary immunodeficiency. It's an injection under the skin. We want to see how well it prevents infections and if it's safe. It will also check how the body uses the medicine.